Zenotech earmarks Rs 60cr investments

Zenotech Laboratories Limited, which had achieved breakeven last year, would be investing about Rs 60 crore in the current year in product development and new facilities.

According to chairman and managing director Jayaram Chigurupati, Zenotech is fast emerging as a speciality generic injectables company and would be launching five new anaesthesia products in a month.

The company, which started its operations in 2003, currently has 15 chemical oncology products.

Refusing to comment on the reports that Ranbaxy Laboratories was likely to acquire 10 per cent of the equity of Zenotech, Chigurupati said that the company was setting up a 100 per cent export-oriented facility at its 50-acre site adjacent to Shapoorji Pallonji Biotech Park near Hyderabad.

At present, Zenotech has a 1.1-lakh sft biologics manufacturing facility at the place.

He said that development of generic biopharmaceuticals and their formulations would continue to remain the main focus for research activities in the company. During 2005-06, the company's turnover stood at Rs 13.5 crore.